1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C. Cho; M-J. Ahn; T.M. Kim; C. Kim; B.Y. Shim; J-Y. Han; A.E. Drilon; H. Lena; J.E. Gomez; J.E. Gray; Mohamed Attia Ramadan Ibrahim Abou Awad; J. Perez; M. Navas; M. Kaul; S. Patel; B. Gao; H. Magnan; P. Rietschel

doi:10.1016/j.annonc.2022.07.1296

1173P Early safety, tolerability, and efficacy of REGN5093 in patients (pts) with MET-altered advanced non-small cell lung cancer (aNSCLC) from a first in human (FIH) study

B.C. Cho(Yonsei University), M-J. Ahn(Samsung Medical Center), T.M. Kim(Seoul National University Hospital), C. Kim(Georgetown University), B.Y. Shim(The Catholic University of Korea St. Vincent's Hospital), J-Y. Han(National Cancer Center), A.E. Drilon(Memorial Sloan Kettering Cancer Center), H. Lena(Centre Hospitalier Universitaire de Rennes), J.E. Gomez(Mount Sinai Medical Center), J.E. Gray(Moffitt Cancer Center), Mohamed Attia Ramadan Ibrahim Abou Awad(Dana-Farber Cancer Institute), J. Perez(Regeneron (United States)), M. Navas(Regeneron (United States)), M. Kaul(Regeneron (United States)), S. Patel(Regeneron (United States)), B. Gao(Regeneron (United States)), H. Magnan(Regeneron (United States)), P. Rietschel(Regeneron (United States))

Annals of Oncology

September 1, 2022

10.1016/j.annonc.2022.07.1296

Cited by 8

Abstract

Related Papers

No related papers found

Powered by citation graph analysis